Fast forward to this week’s report set to to be released on Thursday morning, and we see the stock climbing from the mid-$90’s a month ago to currently $108.21, up nearly 2% on the session. We can gather analysts will be looking for guidance in several areas from the company.
– Will the company announces any new collaborations & drug/technology licensing deals as they did in previous deals with the likes of Bluebird Bio (NASDAQ:BLUE), OncoMed (NASDAQ:OMED), Juno Therapeutics (NASDAQ:JUNO), Acceleron (NASDAQ:XLRN), and Epizyme (NASDAQ:EPZM)?
– Will the company continue to be aggressive buying back its shares? Recently added $3B to its existing share buyback program.
– Are there any updates regarding the 18 phase 3 trials scheduled to be completed by 2018?
These answers and any others that are discussed will definitely have an impact on the iShares Nasdaq Biotechnology (NASDAQ:IBB) ETF, which is down over 16% year-to-date, but similar to Celgene, has started to show some life, rebounding from the $250 levels in late June to where it currently trades today at $285.
Shares of Celgene Corporation are trading at $108.35, up $2.17 (+2.07%) in Wednesday afternoon trading.